What drove COPN.SW stock down intraday on 09 Mar 2026?

COPN.SW stock fell intraday amid position trimming ahead of the 09 Mar 2026 earnings release; traders cited uncertainty over guidance and near-term product sales as the main trigger.

What valuation metrics should I watch for COPN.SW stock?

Watch **PE (33.05)**, **EPS (3.25)**, price-to-book **~4.12**, and free cash flow yield; these show a premium versus historical averages and help assess whether the post-earnings move is justified.

How does Meyka AI view COPN.SW stock after the drop?

Meyka AI rates COPN.SW **78.39/100 (B+, BUY)**, citing strong cash flow and sector positioning, but notes short-term earnings risk and technical oversold conditions.

What price targets apply to COPN.SW stock?

Meyka AI models and our scenarios give a conservative target **CHF 80.00**, a base **CHF 100.00**, and a bullish **CHF 130.00**; use these relative to current **CHF 91.80** and your risk profile.

CH Stocks

COPN.SW Cosmo Pharmaceuticals (SIX) 09 Mar 2026 -15.47% intraday: earnings risk

ByHuzaifa Zahoor March 9, 2026March 9, 2026

Cosmo Pharmaceuticals N.V. (COPN.SW stock) fell 15.47% intraday to CHF 91.80 as investors trimmed positions ahead of the scheduled earnings release on 09 Mar 2026. The slide follows a wide trading range today with a day high CHF 99.90 and day low CHF 89.00, on volume of 81,909 shares. With a trailing PE of 33.05 and EPS of 3.25, traders will watch guidance, margin trends, and product-level sales for Lialda and GI Genius when results arrive later today.